Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
about
NRF2 Induction for NASH Treatment: A New Hope Rises.Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study.Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development.Key Inflammatory Processes in Human NASH Are Reflected in Ldlr-/-.Leiden Mice: A Translational Gene Profiling Study.Reduction of Liver Span and Parameters of Inflammation in Nonalcoholic Fatty Liver Disease Patients Treated with Lycosome Formulation of Phosphatidylcholine: A Preliminary Report.Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions.Recent advances in understanding and managing non-alcoholic fatty liver disease.The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease.Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease.Mitochondrial Stasis Reveals p62-Mediated Ubiquitination in Parkin-Independent Mitophagy and Mitigates Nonalcoholic Fatty Liver DiseaseAmong Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular MortalityBile Acids Activated Receptors Regulate Innate ImmunityTargeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo modelCell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated DisordersAdapted Immune Responses of Myeloid-Derived Cells in Fatty Liver DiseasePathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic ApproachesBiomarkers for hepatocellular carcinoma: What's new on the horizon?Non-Alcoholic Fatty Liver Disease in Overweight Children: Role of Fructose Intake and Dietary PatternThe Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD)Dissociation of Fatty Liver and Insulin Resistance in I148M PNPLA3 Carriers: Differences in Diacylglycerol (DAG) FA18:1 Lipid Species as a Possible ExplanationDNA methylation biomarkers for hepatocellular carcinomaInsulin Resistance in HIV-Patients: Causes and ConsequencesSimple Scores of Fibrosis and Mortality in Patients with NAFLD: A Systematic Review with Meta-AnalysisUrsodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunctionIncreased Serum Uric Acid over five years is a Risk Factor for Developing Fatty LiverBranched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot studyGlobal, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017Serotonin signals through a gut-liver axis to regulate hepatic steatosisGlobal, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
P2860
Q52575751-B6981664-BA19-4116-8AD1-76E28800901CQ54219671-04A591F0-2E4E-4843-AC85-28F33A20F30EQ55023687-C1E105E4-7268-4B5D-B051-4196E1318ACBQ55071759-104C4825-3BA6-4AD9-96D6-0D4623AE6908Q55312591-7F9B5EB2-E67A-4D19-9BCB-7392E183CF28Q55315481-FD1871C8-1BD7-417C-8010-65A62CE0A074Q55359842-9A6FEC4C-6629-40C4-BF32-F904B48ACE4DQ55450597-E27A635E-B6E9-4D8B-830B-FD0246096EACQ55452630-F68A3332-C6C2-4652-9DFF-B6E5A7891996Q57044776-1A4BA79E-8EA6-4EEA-9555-CFF2712E4864Q57070326-124D3438-D390-42B4-9D99-9B0D64942656Q57111959-819857DA-E2D2-46DE-A5DB-8792C2C3B477Q57132035-996C5553-CDEC-4AA5-9AC2-36DA2E5AE28FQ57191819-30ECBC91-33E1-425C-93FB-034CD5834632Q58596151-18226037-318F-45E6-82A9-4DFB2460B27AQ58705640-034865D7-1228-4FF7-8152-D98E4F23616EQ58707823-948FFB92-DE58-422D-949B-123F7ECB5205Q58715994-057800BA-82E5-4FFC-80A2-E077CACD58F6Q58726261-016508B7-E22F-4829-8397-8722C01F1CC8Q58729926-AECA8B2C-BACC-4FAD-8595-F9E8FFD2513CQ58732480-CC8A6736-B346-459D-857D-AE9A526FF779Q58763014-19318281-F02B-4D3C-BEFA-D64E0AE969FBQ58776930-B4193924-6B2A-4B8F-86B2-0B060044AC0DQ58796002-5992417A-E015-434A-A068-A1325FB6D024Q58799660-6087A716-C28F-46C6-81F0-51EB51E26E3AQ59126498-E8FFEFE0-096F-46F8-A48D-24FD0AF74CEEQ59131985-980EDA97-6296-4C24-96A9-261B41A37CFBQ59136627-840CA898-DD91-4725-8251-39D689B3DCDFQ59137381-78566043-0033-46F0-AB27-39228088CACB
P2860
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
@en
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
@nl
type
label
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
@en
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
@nl
prefLabel
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
@en
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
@nl
P2093
P2860
P1476
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
@en
P2093
Jacob George
Linda Henry
Milena Marietti
Mohammed Eslam
Quentin M Anstee
Timothy Hardy
Zobair Younossi
P2860
P2888
P356
10.1038/NRGASTRO.2017.109
P407
P577
2017-09-20T00:00:00Z
P6179
1091858590